insights_auto
Why is LCTX up 2.89%?
Dive Deeperchevron_right
LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
$0.93
arrow_upward
+2.89%(+0.026) 1D
$0.96
arrow_upward
+3.07% (+0.029)bedtimeAfter hours
Closed: Oct 2, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Open
$0.92
High
$0.96
Low
$0.89
Mkt. cap
236.38M
Avg. vol.
1.33M
Volume
1.25M
52-wk high
$2.09
52-wk low
$0.88
EPS
-$0.14
Beta
1.60
Shares outstanding
252.91M
No. of employees
75
Open
$0.92
High
$0.96
Low
$0.89
Mkt. cap
236.38M
Avg. vol.
1.33M
Volume
1.25M
52-wk high
$2.09
52-wk low
$0.88
EPS
-$0.14
Beta
1.60
Shares outstanding
252.91M
No. of employees
75
News stories
From web sources and news partners
MarketBeat
·
15 minutes ago
Xometry (NASDAQ:XMTR) CEO Sanjeev Singh Sahni Sells 1,112 Shares of Stock
Simply Wall Street
·
1 hour ago
Ionis Pharmaceuticals Fell 45% With The Case Still Split
The Business Times
·
35 minutes ago
US: Equities close higher as softer jobs data quiets rate-hike expectations
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc